Real-World Treatment Patterns and Outcomes in First-Line Small-Cell Lung Cancer (SCLC) in France
Author(s)
Didier Debieuvre, PhD1, Julien Vernon, MSc2, Jessie Wang, PhD3, Sachin Patel, MSc4, Eric Briens, PhD5, Leleu Olivier, PhD6, Patrick Massoma Peh, PhD2, Mélina Gilberg, MSc2, Pastel Malaika, PharmD3, Lionel Falchero, PhD7.
1Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Mulhouse, France, 2Amgen SAS, Courbevoie, France, 3Amgen Inc., Thousand Oaks, CA, USA, 4Amgen Ltd, Uxbridge, United Kingdom, 5Centre Hospitalier Saint-Brieuc, Saint-Brieuc, France, 6Centre Hospitalier Abbeville, Abbeville, France, 7Hopitaux Nord-Ouest, Villefranche-Sur-Saône, France.
1Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Mulhouse, France, 2Amgen SAS, Courbevoie, France, 3Amgen Inc., Thousand Oaks, CA, USA, 4Amgen Ltd, Uxbridge, United Kingdom, 5Centre Hospitalier Saint-Brieuc, Saint-Brieuc, France, 6Centre Hospitalier Abbeville, Abbeville, France, 7Hopitaux Nord-Ouest, Villefranche-Sur-Saône, France.
OBJECTIVES: SCLC is an aggressive malignancy with high unmet need. Real-world data are essential to understand treatment effectiveness and care patterns outside clinical trials, especially in a high-mortality disease like SCLC. We characterized real-world treatment patterns and clinical outcomes among patients with SCLC receiving 1L therapy in France.
METHODS: This retrospective observational study used ESCAP-2020, an ancillary study of KBP-2020 a French prospective cohort of patients diagnosed with primary lung cancer in 2020 across non-academic public hospitals. Patients diagnosed with limited-stage (LS) or extensive-stage (ES) SCLC who received 1L systemic therapy were included. Descriptive analyses were conducted for baseline characteristics, treatment patterns, real-world overall survival (rwOS), and progression-free survival (rwPFS).
RESULTS: Of 910 patients diagnosed with SCLC in 2020, 758 patients (83.3%) received 1L therapy. Of these, 80.5% were diagnosed with ES, 16.5% had LS, and 3% had missing stage. The mean age at 1L initiation was 65.6 years (SD: 9.87) in LS and 67 years (SD: 8.64) in ES; 36.8% of LS and 34.3% of ES patients were female. Compared to ES, patients with LS had better ECOG performance status (0/1: 88.7% vs 68.6%). Most patients, regardless of stage, had a history of smoking. Among LS patient, 96% received platinum-etoposide (PE), with 84.2% also receiving radiation therapy; 15% underwent surgery, and 8.8% received PE with immunotherapy (IO). In ES, 51% received PE + IO, 44.1% PE alone, and 4.9% other regimens. For survival outcomes, median rwOS was 24.6 months for LS and 8.0 months for ES. The median rwPFS was 12.4 and 5.0 months, respectively.
CONCLUSIONS: This analysis highlights substantial unmet needs in SCLC, particularly in the ES population, where survival outcomes remain poor and IO use was limited due to its recent availability in 2020. These real-world findings align with prior evidence, reinforcing the need for more durable therapies to improve outcomes.
METHODS: This retrospective observational study used ESCAP-2020, an ancillary study of KBP-2020 a French prospective cohort of patients diagnosed with primary lung cancer in 2020 across non-academic public hospitals. Patients diagnosed with limited-stage (LS) or extensive-stage (ES) SCLC who received 1L systemic therapy were included. Descriptive analyses were conducted for baseline characteristics, treatment patterns, real-world overall survival (rwOS), and progression-free survival (rwPFS).
RESULTS: Of 910 patients diagnosed with SCLC in 2020, 758 patients (83.3%) received 1L therapy. Of these, 80.5% were diagnosed with ES, 16.5% had LS, and 3% had missing stage. The mean age at 1L initiation was 65.6 years (SD: 9.87) in LS and 67 years (SD: 8.64) in ES; 36.8% of LS and 34.3% of ES patients were female. Compared to ES, patients with LS had better ECOG performance status (0/1: 88.7% vs 68.6%). Most patients, regardless of stage, had a history of smoking. Among LS patient, 96% received platinum-etoposide (PE), with 84.2% also receiving radiation therapy; 15% underwent surgery, and 8.8% received PE with immunotherapy (IO). In ES, 51% received PE + IO, 44.1% PE alone, and 4.9% other regimens. For survival outcomes, median rwOS was 24.6 months for LS and 8.0 months for ES. The median rwPFS was 12.4 and 5.0 months, respectively.
CONCLUSIONS: This analysis highlights substantial unmet needs in SCLC, particularly in the ES population, where survival outcomes remain poor and IO use was limited due to its recent availability in 2020. These real-world findings align with prior evidence, reinforcing the need for more durable therapies to improve outcomes.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO209
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
Oncology